Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma

Journal of Pathology

Volumn 182, Issue 3, 1997, Pages 347-355

  Bramhall, Simon R ^a,b   Neoptolemos, John P ^b   Stamp, Gordon W H ^c   Lemoine, Nicholas R ^c  

^a CITY HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

MMP2; MTMMP; Pancreatic carcinoma; TIMP2

Indexed keywords

METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR;

ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; PANCREAS CARCINOMA; PRIORITY JOURNAL;

BLOTTING, NORTHERN; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; DNA PROBES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METALLOENDOPEPTIDASES; PANCREATIC NEOPLASMS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED;

EID: 0030801093     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J     Document Type: Article

References (58)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J clin 1993; 43: 7-26.
2. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82: 111-115.
3. Nagakawa T, Konishi I, Higashino Y, et al. The spread and prognosis of carcinoma in the region of the pancreatic head. Jpn J Surg 1989; 19: 510-518.
4. Nagakawa T, Kayahara M, Ueno K, et al. A clinicopathologic study on neural invasion in cancer of the pancreatic head. Cancer 1992; 69: 930-935.
5. Mollenhauer J, Roether I, Kern HF. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas 1987; 2: 14-24.
6. Hart IR, Goode NT, Wilson RE, Molecular aspects of the metastatic cascade. Biochim Biophys Acta 1989; 989: 65-84.
7. Liotta LA, Stetler-Stevenson WG, Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51(Suppl): 5054s-5059s.
8. Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int J Oncol 1993; 2: 861-872.
9. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
10. Murphy GJP, Murphy G, Reynolds JJ. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 1991; 289: 4-7.
11. Will H, Hinzman B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602-608.
12. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J Biol Chem 1995; 270: 23013-23020.
13. Sellers A, Murphy G, Meikle MC, Reynolds JJ, Rabbit bone collagenase inhibitor blocks the activity of other neutral metalloproteinases. Biochem Biophys Res Commun 1979; 87: 581-587.
14. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264: 17374-17378.
15. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C. Structure and expression in breast tumours of human TIMP-3, a new member of the metalloproteinase inhibitor family. Camer Res 1994; 54: 2091-2094.
16. Ponton A, Coulombe B, Skup D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res 1991; 51: 2138-2143.
17. Basset P, Bellocq JP, Wolf C. eT al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
18. Poulsom R, Pignatelli M, Stetler-Stevenson WG, eT al. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-396.
19. Poulsom R, Hanby AM, Pignatelli M. et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993; 46: 429-436.
20. Okada Y, Tsuchiya H, Shimizu H, et al. Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor a. Biochem Biophys Res Commun 1990; 171: 610-617.
21. Overall CM, Wrana JL, Sodek J, Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J Biol Chem 1989; 264: 1860-1870.
22. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest 1990; 86: 1204-1210.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
24. Chomczynski P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal Biochem 1992; 201: 134-139.
25. Bramhall SR, Stamp GWH, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2). stromelysin (MMP3) and tissue inhibitor of the metalloproteinase (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996; 73: 972-978.
26. Taniguchi S, Iwamura T, Katsuki T. Correlation between spontaneous metastatic potential and type 1 collagenolytic activity in a human pancreatic cell line (SUIT-2) and sublines. Clin Exp Metastasis 1992; 10: 259-266.
27. Moll UM, Lane B, Zucker S, Suzuki K, Nagase H. Localisation of collagenase at the basal plasma membrane of a human pancreatic carcinoma cell line. Cancer Res 1990; 50: 6995-7002.
28. Zucker S, Moll UM, Lysik RM, DiMassimo EI, Schwedes JW, Liotta LA. Extraction of type IV collagenase/gelatinase from plasma membranes of human pancreatic cancer cells. Matrix Suppl 1992; 1: 411.
29. Van-Der-Stappen JWJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 1990; 45: 1071-1078.
30. Wirl G, Frick J. Collagenase - a marker enzyme in human bladder cancer? Urol Res 1979; 7: 103-108.
31. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-68.
32. Bernhard EJ, Muschel RJ, Hughes EN. Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 1990; 50: 3872-3877.
33. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213-17221.
34. Yamagata S, Ito Y, Tanaka R, Shimizu S. Gelatinases of metastatic cell lines of murine colonic carcinoma as detected by substrate-gel electrophoresis. Biochem Biophys Res Commun 1988; 151: 158-162.
35. Yamagata S, Tanaka R, Ito Y, Shimizu S. Gelatinases of murine metastatic tumour cells. Biochem Biophys Res Commun 1989; 158: 228-234.
36. Nakajima M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987; 47: 4869-4876.
37. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992; 16: 500-507.
38. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DE. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991; 49: 666-672.
39. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-413.
40. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). J Biol Chem 1989; 264: 17374-17378.
41. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988; 48: 6863-6871.
42. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 1985; 75: 99-103.
43. r 72,000 and 92,000 type IV collagenases in human skin cancers by in-situ hybridisation. Cancer Res 1992; 52: 1336-1341.
44. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 1990; 136: 585-592.
45. r 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439-444.
46. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995; 104: 678-684.
47. McDonnell S, Navre M, Coffey RJ, Matrisian LM. Expression and localisation of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinogenesis 1991; 4: 527-533.
48. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614-618.
49. Saarialho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995; 105: 190-196.
50. Crabbe T, Willenbrock F, Eaton D, et al. Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry 1992; 31: 8500-8507.
51. Matrisian LM, Bowden GT. Stromelysin/transin and tumor progression. Semin Cancer Biol 1990; 1: 107-115.
52. Polette M, Clavel C, Birembaut P, De-Clerck YA. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 1993; 189: 1052-1057.
53. Muller D, Wolf C, Abecassis J, et al. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993; 53: 165-169.
54. Muller D, Breathnach R, Engelmann A, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 1991; 48: 550-556.
55. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775-779.
56. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-708.
57. Lee CS, Montebello J, Georgiou T, Rode J. Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis. Int J Exp Pathol 1994; 75: 79-83.
58. Wang Z-H, Manabe T, Ohshio G, et al. Immunohistochemical study of heparan sulfate proteoglycan in adenocarcinomas of the pancreas. Pancreas 1994; 9: 758-763.